Compare Quest Diagnostics Inc (DGX) vs ZIM Integrated Shipping Services Ltd (ZIM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? Quest Diagnostics Inc trades at $205.19 (market cap $22.80B), while ZIM Integrated Shipping Services Ltd trades at $24.55 (market cap $2.94B). The key difference: Quest Diagnostics Inc is far larger — about 7.8× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays the higher dividend (20.16%). Which is the better fit depends on your goals.
| DGX | ZIM | |
|---|---|---|
Market Cap | $22.80B | $2.94B |
Sector | Health | Industrials |
52-Week High | $216.02 | $29.27 |
52-Week Low | $166.42 | $12.44 |
Enterprise Value | $28.82B | $6.79B |
Dividend Yield | 1.67% | 20.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
ZIM Integrated Shipping Services (ZIM) trades at $23.80, down 0.71% on the day, amid bearish technical signals and mixed fundamental performance. The stock faces pressure from regulatory setbacks to its Hapag-Lloyd merger, though recent news highlights rival takeover interest. Financially, 2025 revenue was $6.90B with net income of $479.20M, but 2026 projections show declining profitability. Analyst consensus is split evenly between Hold and Sell, with a price target of $16.75, well below current levels.
The outlook for ZIM is cautious due to merger uncertainty and weakening earnings. Investment opportunities exist if takeover bids materialize, but risks include regulatory hurdles, freight rate volatility, and cash flow pressures. The stock's current price trades at a discount to asset value, yet analyst skepticism and bearish technicals suggest limited near-term upside without positive deal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About ZIM Integrated Shipping Services Ltd
ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →
